Results 141 to 150 of about 4,120 (174)
Some of the next articles are maybe not open access.

Orthostatic Hypotension

Archives of Internal Medicine, 1984
The maintenance of adequate upright BP requires both a baroreceptor-mediated feedback loop and an effective circulating blood volume. Although functional disruptions of these mechanisms are reversible and common, several permanent and often progressive neurologic disorders exist that interfere with necessary reflexes and orthostatic BP control ...
openaire   +3 more sources

Management of neurogenic orthostatic hypotension in the heart failure patient

Autonomic Neuroscience, 2020
Neurogenic orthostatic hypotension (nOH) is a common comorbidity in patients with neurodegenerative diseases. It is associated with an increased risk of falls, incident cardiovascular disease, and all-cause mortality. There are over 5 million individuals in the U.S. with heart failure (HF) with an associated 50% mortality rate at 5 years.
James A.S. Muldowney, Debra Dixon
openaire   +3 more sources

Droxidopa approved for neurogenic orthostatic hypotension

American Journal of Health-System Pharmacy, 2014
Droxidopa, a synthetic amino acid precursor of norepinephrine, has been approved as oral therapy for the treatment of neurogenic orthostatic hypotension, FDA and Chelsea Therapeutics announced on February 18.
openaire   +2 more sources

Efficacy of Midodrine for Neurogenic Orthostatic Hypotension

JAMA: The Journal of the American Medical Association, 1997
To the Editor. —Orthostatic hypotension due to autonomic failure is an incapacitating condition for which treatment, despite various drug interventions (eg, yohimbine, metoclopramide, β-blockers, somatostatin analog) is not yet resolved. Therefore, the encouraging results of the study of Dr Low and colleagues 1 are potentially of great importance ...
openaire   +2 more sources

Droxidopa for the treatment of neurogenic orthostatic hypotension in neurodegenerative diseases

Expert Opinion on Pharmacotherapy, 2019
L-threo-3,4-dihydroxyphenylserine (droxidopa), a pro-drug metabolized to norepinephrine in nerve endings and other tissues, has been commercially available in Japan since 1989 for treating orthostatic hypotension symptoms in Parkinson's disease (PD) patients with a Hoehn & Yahr stage III rating, as well as patients with Multiple System Atrophy (MSA ...
Santiago Pérez-Lloret   +3 more
openaire   +4 more sources

Neurogenic orthostatic hypotension as the initial feature of Parkinson disease

Clinical Autonomic Research, 2012
Autonomic failure is a common finding in patients with Parkinson disease (PD). Here we describe a patient with PD in whom autonomic symptoms began 3 years before motor deficits.
V. Milazzo   +5 more
openaire   +4 more sources

Cerebellar impairment during an orthostatic challenge in patients with neurogenic orthostatic hypotension

Clinical Neurophysiology, 2019
Compare activation patterns within the cortical autonomic network in patients with neurogenic orthostatic hypotension (NOH) versus healthy age-matched controls during an orthostatic challenge.Fifteen health controls and 15 NOH patients performed 3 Valsalva maneuvers, and 5-min of lower-body negative pressure (LBNP) during a functional brain MRI ...
Jacquie Baker   +5 more
openaire   +3 more sources

New Developments in the Management of Neurogenic Orthostatic Hypotension

Current Cardiology Reports, 2014
Orthostatic hypotension (OH) is defined as a sustained reduction of ≥ 20 mmHg systolic blood pressure or ≥ 10 mmHg diastolic blood pressure upon standing for ≤ 3 min. Orthostatic hypotension is commonly associated with hypertension, and its prevalence is highest in those with uncontrolled hypertension compared to those with controlled hypertension or ...
openaire   +3 more sources

The arterial baroreflex in neurogenic orthostatic hypotension

Clinical Autonomic Research, 2023
Phillip, Low, Wolfgang, Singer
openaire   +2 more sources

Home - About - Disclaimer - Privacy